Dr. Trever Bivona is a cell and molecular biologist and a medical oncologist. He received his MD and PhD degrees from NYU School of Medicine, followed by internal medicine training at the Brigham and Women’s Hospital/Harvard Medical School in Boston, and medical oncology and post-doctoral research training at the Memorial Sloan-Kettering Cancer Center in New York. Dr. Bivona then joined the faculty at the University of California, San Francisco in 2011 where he is currently a Professor in the Department of Medicine, Hematology/Oncology division, and the Department of Cellular and Molecular Pharmacology, and a member of the Helen Diller UCSF Comprehensive Cancer Center. Dr. Bivona is also an appointed Senior Investigator at the Chan-Zuckerberg Biohub, San Francisco. Dr. Bivona directs a basic and translational research program investigating oncogene signaling pathways and the molecular basis of response and resistance to cancer therapeutics, with a major focus on kinase and RAS signaling. Recent work by Dr. Bivona and colleagues uncovered a new form of oncogenic kinase and RAS signaling through liquid-liquid phase separation and biomolecular condensation. Dr. Bivona is currently Principal Investigator of the NIH/NCI Bay Area and Anderson Acquired Resistance to Therapy Network (ARTNet) Center. He received a NIH Director’s New Innovator Award and is an elected member of the American Society for Clinical Investigation.